{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:01:58Z","timestamp":1776902518701,"version":"3.51.2"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:00:00Z","timestamp":1535587200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.00969","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:42:55Z","timestamp":1535589775000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Chinese Herbal Medicine for Myasthenia Gravis: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"9","author":[{"given":"Shuang","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Bei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Qing","family":"Rong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Yu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Qing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,8,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/cei.13006","article-title":"The effect of interleukin (IL)-21 and CD4(+) CD25(++) T cells on cytokine production of CD4(+) responder T cells in patients with myasthenia gravis.","volume":"190","author":"Alahgholi-Hajibehzad","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1586\/1744666X.2015.1047345","article-title":"The role of T regulatory cells in immunopathogenesis of myasthenia gravis: implications for therapeutics.","volume":"11","author":"Alahgholi-Hajibehzad","year":"","journal-title":"Exp. Rev. Clin. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jneuroim.2015.03.008","article-title":"Regulatory function of CD4+CD25+ T cells inpatients with myasthenia gravis is associated with phenotypic changes and STAT5signaling: 1,25-Dihydroxyvitamin D3 modulates the suppressor activity.","volume":"281","author":"Alahgholi-Hajibehzad","year":"","journal-title":"J. Neuroimmunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jaut.2015.09.005","article-title":"Suppression of experimental autoimmune myasthenia gravis by autologous T regulatory cells.","volume":"67","author":"Aricha","year":"2016","journal-title":"J. Autoimmun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.5142\/jgr.2012.36.4.375","article-title":"Ginsenoside Rp1 exerts anti-inflammatory effects via activation of dendritic cells and regulatory T Cells.","volume":"36","author":"Bae","year":"2012","journal-title":"J. Ginseng Res."},{"key":"B6","author":"Bao","year":"2016","journal-title":"B.Clinical Observation on Myasthenia Gravis Treated by Huangqi Compound Granules."},{"key":"B7","first-page":"13","article-title":"Clinical observation on myasthenia gravis treated by huangqi compound granules.","volume":"19","author":"Bao","year":"2016","journal-title":"J. Guangxi Univ. Chin. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score.","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials.","volume":"45","author":"Benatar","year":"2012","journal-title":"Muscle Nerve"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1007\/s10753-014-9887-0","article-title":"Ginsenoside metabolite compound k alleviates adjuvant-induced arthritis by suppressing T cell activation.","volume":"37","author":"Chen","year":"","journal-title":"Inflammation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1139\/bcb-2014-0008","article-title":"Astragalus membranaceus modulates Th1\/2 immune balance and activates PPARgamma in a murine asthma model.","volume":"92","author":"Chen","year":"","journal-title":"Biochem. Cell Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.intimp.2016.08.028","article-title":"Ginsenoside Rb1: the new treatment measure of myasthenia gravis.","volume":"41","author":"Chen","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"W7","DOI":"10.7326\/IsTranslatedFrom_M17-2977_1","article-title":"CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration (traditional Chinese version).","volume":"167","author":"Cheng","year":"2017","journal-title":"Ann. Int. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3969\/j.issn.1006-2963.2011.05.019","article-title":"Chinese expert consensus for the diagnosis and treatment of myasthenia gravis.","volume":"18","year":"2011","journal-title":"Chin. J. Neuro Immunol. Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1021\/acs.jcim.5b00449","article-title":"Discovering new acetylcholinesterase inhibitors by mining the buzhongyiqi decoction recipe data.","volume":"55","author":"Cui","year":"2015","journal-title":"J. Chem. Inform. Model."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0892-8","article-title":"Regulatory T cells in multiple sclerosis and myasthenia gravis.","volume":"14","author":"Danikowski","year":"2017","journal-title":"J. Neuroinflamm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1196\/annals.1405.033","article-title":"Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis.","volume":"1132","author":"Drachman","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jep.2011.12.017","article-title":"Guidelines for randomised controlled trials investigating Chinese herbal medicine.","volume":"140","author":"Flower","year":"2012","journal-title":"J. Ethnopharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies.","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","article-title":"Maintenance immunosuppression in myasthenia gravis.","volume":"369","author":"Gotterer","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"B21","author":"Higgins","year":"2011","journal-title":"Cochrane Handbook for Systematic Reviews of Q15 Interventions Version 5.1.0."},{"key":"B22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America.","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/351856","article-title":"Red ginseng extract ameliorates autoimmune arthritis via regulation of STAT3 pathway, Th17\/Treg balance, and osteoclastogenesis in mice and human.","volume":"2014","author":"Jhun","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"B24","doi-asserted-by":"publisher","first-page":"518942","DOI":"10.1155\/2014\/518942","article-title":"Clinical study of effects of jian ji ning, a Chinese herbal medicine compound preparation, in treating patients with myasthenia gravis via the regulation of differential MicroRNAs expression in serum.","volume":"4","author":"Jiang","year":"2014","journal-title":"Evid-Based Complement. Alternat."},{"key":"B25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.intimp.2012.11.009","article-title":"CD4+CD25+Foxp3+ T cells contribute to the antiasthmatic effects of Astragalus membranaceus extract in a rat model of asthma.","volume":"15","author":"Jin","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"B26","author":"Ju","year":"2003","journal-title":"Randomized Controlled Trial on TanWei Capsule and Prednisone for Myasthenia Gravis."},{"key":"B27","author":"Lai","year":"2013","journal-title":"Clinical Study on Bupi Qiangli Compound Immunomodulatory Effect on Spleen and Kidney Deficiency Type Myasthenia Gravis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejphar.2015.06.011","article-title":"Anti-inflammatory effects of ginsenoside Rg1 and its metabolites ginsenoside Rh1 and 20(S)-protopanaxatriol in mice with TNBS-induced colitis.","volume":"762","author":"Lee","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/(SICI)1097-0258(19990815)18:15<1903::AID-SIM188>3.0.CO;2-F","article-title":"Statistical principles for clinical trials (ICH E9): an introductory note on aninternational guideline.","volume":"18","author":"Lewis","year":"1999","journal-title":"Stat. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/(SICI)1097-0258(19990815)18:15<1903::AID-SIM188>3.0.CO;2-F","article-title":"Guidance for Industry Statistical Principles for Clinical Trials ICH Topic E9 an introductory note on an international guideline.","volume":"18","author":"Lewis","year":"2003","journal-title":"Stat. Med."},{"key":"B31","author":"Li","year":"2012","journal-title":"Clinical Observation and Immunoregulatory Mechanism of Myasthenia Gravis withYiqi Qushi Fang."},{"key":"B32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1146\/annurev-physiol-022516-034255","article-title":"Neuromuscular junction formation, aging, and disorders.","volume":"80","author":"Li","year":"2018","journal-title":"Annu. Rev. Physiol."},{"key":"B33","author":"Liang","year":"2011","journal-title":"Ji Li Kang Drinking of Observe Clinical Effects Treatment of Myasthenia Graris of Spleen Deficient Type."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.11842\/wst.2015.07.028","article-title":"Chinese herbs for treatment of myasthenia gravis: a meta-analysis of randomized control trials.","volume":"17","author":"Lyu","year":"2015","journal-title":"World Sci. Technol. Mod. Tradit. Chin. Med. Mater. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nature05478","article-title":"FoxP3 occupancy and regulation of key target genes during T-cell stimulation.","volume":"445","author":"Marson","year":"2007","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jneuroim.2010.03.016","article-title":"Clinica limplication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients.","volume":"225","author":"Masuda","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000279334","article-title":"The incidence of myasthenia gravis: a systematic review.","volume":"34","author":"McGrogan","year":"2010","journal-title":"Neuroepidemiology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.cct.2013.09.003","article-title":"The ethics of placebo-controlled trials: methodological justifications.","volume":"36","author":"Millum","year":"2013","journal-title":"Contemp. Clin. Trials"},{"key":"B39","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"B40","author":"Niu","year":"2009","journal-title":"Clinical and Experimental Study on Huangqi Compound for Myasthenia Gravis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2174\/1570159X11311040003","article-title":"Nature: a substantial source of auspicious substances with acetylcholinesterase inhibitory action.","volume":"11","author":"Orhan","year":"2013","journal-title":"Curr. Neuropharmacol."},{"key":"B42","author":"Ou","year":"2005","journal-title":"Clinical Study on Qiangjijianliyin for Myasthenia Gravis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1016\/j.transproceed.2010.08.032","article-title":"Astragalus membranaceus injection delayed allograft survival related with CD4+ CD25+ regulatory T cells.","volume":"42","author":"Qu","year":"2010","journal-title":"Transplant. Proc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance.","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/nyas.13537","article-title":"MGFA task force on MG treatment guidance. Developing treatment guidelines for myasthenia gravis.","volume":"1412","author":"Sanders","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myastheniagravis: executive summary.","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/eji.201445064","article-title":"IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis.","volume":"45","author":"Schaffert","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000251","article-title":"CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.","volume":"7","author":"Schulz","year":"2010","journal-title":"PLoS Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3969\/j.Issn.1674-4616.2014.02.002","article-title":"Clinical study on treatment of myasthenia gravis with yiqi chushi recipe.","volume":"2","author":"Shuang","year":"2014","journal-title":"Res. Integr. Tradit Chin. Western Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for the treatment of autoimmune neuromuscular transmission disorders.","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"B51","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients.","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J. Biol. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/nyas.13591","article-title":"An imbalance between regulatory t cells and t helper 17 cells in acetylcholine receptor-positive myasthenia gravis patients.","volume":"1413","author":"Villegas","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7504\/nk2008S2112","article-title":"Clinical observation of 60 cases of myasthenia gravis with fuyuan yiji capsule and pyridostigmine bromid.","volume":"2","author":"Wang","year":"2008","journal-title":"Chin. J. Practic. Int. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3760\/j.issn:1006-7876.1997.02.007","article-title":"A clinical absolute and relative score system for myasthen ia gravis.","volume":"30","author":"Wang","year":"1997","journal-title":"Chin. J. Neurol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jep.2009.05.013","article-title":"Beneficial effect of Bupleurum polysaccharides on autoimmune disease induced by Campylobacter jejuni in BALB\/c mice.","volume":"124","author":"Wang","year":"2009","journal-title":"J. Ethnopharmacol."},{"key":"B56","author":"Xu","year":"2006","journal-title":"The Clinical Research and the Mechanism Study in Immunological Regulation of Zhongjiling Tablet in Treating Myasthenia Gravis."},{"key":"B57","first-page":"4","article-title":"Clinical study on treatment of myasthenia gravis with zhong Ji Ling tablets.","volume":"11","author":"Xu","year":"2004","journal-title":"J. Beijing. Univ. TCM"},{"key":"B58","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3969\/j.issn.1006-2963.2000.04.001","article-title":"Strengthening clinical and basic collaborative study on myasthenia gravis (Commentary).","volume":"7","author":"Xu","year":"2000","journal-title":"Chin. J. Neuroimmunol. Neurol."},{"key":"B59","first-page":"48","author":"Xu","year":"2003","journal-title":"Neuroimmunology."},{"key":"B60","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.bcp.2017.07.002","article-title":"Chinese herbal medicine for Alzheimer\u2019s disease: clinical evidence and possible mechanism of neurogenesis.","volume":"141","author":"Yang","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.3748\/wjg.v22.i11.3175","article-title":"Astragalus polysaccharide attenuates rat experimental colitis by inducing regulatory T cells in intestinal Peyer\u2019s patches.","volume":"22","author":"Zhao","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/ene.13535","article-title":"A nationwide epidemiological study of myasthenia gravis in Latvia.","volume":"25","author":"Zieda","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3969\/j.issn.1674-7860.2015.28.041","article-title":"Effective observation on treating myasthenia gravis with the Buzhong Yiqi decoction plus hormone.","volume":"7","author":"Zu","year":"2015","journal-title":"Clin. J. Chin. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00969\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:43:02Z","timestamp":1535589782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00969\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,30]]},"references-count":63,"alternative-id":["10.3389\/fphar.2018.00969"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.00969","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,30]]},"article-number":"969"}}